What is the recommended treatment for a patient with class V (membranous) lupus nephritis who is refractory to belimumab?

Treatment of Class V (Membranous) Lupus Nephritis Refractory to Belimumab

For class V lupus nephritis that has failed belimumab therapy, switch to cyclophosphamide or add a calcineurin inhibitor (tacrolimus) to your current regimen, as these agents have demonstrated efficacy in refractory membranous lupus nephritis. 1

Algorithmic Approach to Refractory Class V LN

Step 1: Verify Treatment Failure

Before switching therapy, confirm true refractoriness by:

• Checking adherence to prescribed medications
• Ensuring adequate belimumab dosing (10 mg/kg IV monthly after loading)
• Assessing response timeframe: Allow 6-12 months before declaring treatment failure, as proteinuria improvement is continuous and variable 1
• Measuring drug levels if on concomitant mycophenolate (MPA levels should be therapeutic)

Step 2: Consider Repeat Biopsy

A repeat kidney biopsy should be performed if there is concern for:

• Chronicity/irreversible damage rather than active inflammation
• Alternative diagnosis (e.g., thrombotic microangiopathy)
• Mixed class disease that was underappreciated initially 1

Step 3: Select Alternative Immunosuppression

Primary Options:

1. Cyclophosphamide (if not previously used)

   • The KDIGO 2024 guidelines specifically recommend cyclophosphamide for class V LN with nephrotic-range proteinuria when MMF is ineffective 1
   • Maintains remission longer than CNIs (no relapses within 1 year vs. 40% relapse rate with CNIs) 1
   • Can be given as IV pulses or oral formulation

2. Tacrolimus-based triple therapy

   • Glucocorticoids + tacrolimus + low-dose mycophenolate achieved 33.1% complete remission vs. 7.8% with cyclophosphamide/azathioprine in class V LN 1
   • Tacrolimus dose: 0.06-0.08 mg/kg/day or 0.1-0.2 mg/kg/day, targeting trough levels 3-6 ng/mL 2, 3
   • Particularly effective for nephrotic syndrome presentation 1
   • Faster resolution of proteinuria (76.2% reduction at 12 weeks) compared to conventional therapy 3

3. Rituximab (with or without continuation of belimumab)

   • Response rates of 40-60% reported in small studies 1
   • Emerging data suggests rituximab followed by belimumab or telitacicept may be effective in refractory cases, with 80% achieving objective remission and 76% achieving complete renal response 4
   • The CALIBRATE study showed rituximab + belimumab combination was safe, though not superior to rituximab alone (52% vs 41% response, p=0.4) 5

Step 4: Optimize Supportive Care

Regardless of immunosuppression choice:

• Maximize renin-angiotensin system blockade (ACE inhibitor or ARB)
• Strict blood pressure control (target <130/80 mmHg)
• Continue hydroxychloroquine if not already prescribed
• Manage nephrotic syndrome complications: anticoagulation for high thrombotic risk, lipid management, edema control 1

Critical Nuances and Pitfalls

Why Belimumab May Have Failed

Important caveat: Post-hoc analysis of the BLISS-LN trial revealed that patients with pure class V LN did not benefit from belimumab addition in terms of primary efficacy renal response 5, 6. The benefit was primarily seen in proliferative (class III/IV) disease. This suggests belimumab may not be the optimal biologic for pure membranous LN.

Timing Considerations

• Don't switch too early: Median time to achieve proteinuria <0.5 g/g was 3.6 months with voclosporin, but some patients require >12 months 1
• Don't wait too long: Persistent nephrotic-range proteinuria increases risks of thrombosis, infection, and progressive CKD 1
• Assess response at 6-12 months, but recognize improvement continues beyond this timeframe

CNI-Specific Warnings

• High relapse rate (40%) within 1 year of discontinuation 1
• Requires therapeutic drug monitoring (tacrolimus trough 3-6 ng/mL)
• May need prolonged maintenance therapy
• Monitor for nephrotoxicity with serial creatinine measurements

Cyclophosphamide Considerations

• Fertility preservation counseling essential for women of childbearing age
• Cumulative dose limits to reduce bladder toxicity and malignancy risk
• Consider limiting to 6 months of therapy 1

Practical Recommendation

For your patient with class V LN refractory to belimumab, I recommend:

1. First-line switch: Glucocorticoids + tacrolimus (0.06-0.08 mg/kg/day) + low-dose mycophenolate (if not already on adequate dose), given the superior complete remission rates (33.1%) and faster proteinuria reduction 1

2. Alternative if CNI contraindicated: Cyclophosphamide (IV or oral) for 6 months, as it maintains longer remission than CNIs 1

3. For truly refractory cases: Consider rituximab, potentially followed by continuation or re-initiation of belimumab, based on emerging evidence showing 76-80% complete response rates in refractory LN 4

Monitor response at 6 and 12 months using proteinuria reduction (goal <0.5 g/g for complete response or >50% reduction to <3 g/g for partial response) and stable/improved eGFR (±10-15% of baseline) 1.